上海，2024年11月12日 - 药明康德近日宣布，公司在2024年标普全球企业可持续发展评估（S&P Global Corporate Sustainability Assessment，CSA）中获得行业最高分，位列全球“生命科学工具与服务”领域第一[1]。 “此次评估充分展现了药明康德在全球化运营中不断提升应对环境、社会及管治（ESG）相关风险和机遇的能力，进一步证明了公司在ESG实践中的卓越表现，以及对可持续发展的坚定承诺，”药明康德副董事长兼ESG委员会主席胡正国先生表示，“我们始终坚定不移地将ESG理念嵌入公司全球化运营的核心战略，努力与行业同仁携手构建更健康、更可持续的未来。” CSA是全球领先的企业可持续发展评估工具，对行业内的公司在经济、环境和社会标准上的信息披露和绩效表现给出量化评分。作为第三方独立、可信的行业对标基准，CSA将企业的可持续发展表现与其商业战略联系起来，全面反映该公司的可持续发展管理水平。 在2024年CSA评估中，药明康德获得了80分（满分100分）的优异成绩，相较2023年提升了11分。同时，公司在102项评估问题中取得43项满分，包括风险治理、行为准则、供应商评估和发展、气候风险管理、气候相关财务信息披露、人力资本投资回报率和职业健康安全计划等。 作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德将ESG理念融入公司战略和运营的方方面面。2024年，药明康德连续第四年被MSCI评为ESG AA级；2023和2024年，公司连续2年入选标普全球可持续发展年鉴和富时罗素社会责任指数系列，并同时获评Sustainalytics“行业最高评级”和“区域最高评级”企业；2024年，公司加入了“联合国全球契约组织”（United Nations Global Compact，UNGC），承诺支持全球契约十项原则；2023年，公司加入“科学碳目标倡议”（Science Based Targets initiative，SBTi）以减少碳排放。药明康德出色的ESG表现也受到了CDP和EcoVadis等全球ESG评级机构的高度认可。 关于药明康德药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、精准医疗研发、测试和生产等领域。2024年，药明康德连续第四年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的6,000多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
[1] 截至2024年11月12日
WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment Shanghai, November 11, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Global Corporate Sustainability Assessment (CSA), as of November 11, 2024. “This achievement demonstrates our company’s success in enhancing its capability to address environmental, social and governance (ESG) related risks and opportunities across its global operations,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. He added, “WuXi AppTec’s leading position also underscores our unwavering commitment to sustainable development and exceptional performance in ESG practices. By embedding ESG initiatives at the core of our global operations, WuXi AppTec is contributing to a healthier and more sustainable world.” The S&P Global CSA is a leading tool for corporate sustainability assessments that quantifies companies’ disclosure of information and performance across a wide range of industry-specific economic, environmental, and social criteria. As an industry benchmark, the CSA links a company’s sustainability performance with its business strategy, providing a credible reflection of a company’s sustainability management level. WuXi AppTec achieved a 2024 CSA score of 80 out of 100 points, an impressive 11-point increase over 2023. The company received full marks in 43 out of 102 areas evaluated in the CSA, including Risk Governance, Code of Conduct, Supplier Assessment and Development, Climate Risk Management, Task Force Climate Related Financial Disclosure (TCFD), Human Capital Return on Investment, and Occupational Health Programs. As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its global business operations. As a result, its outstanding ESG performance has been widely recognized by other major global ESG rating agencies such as MSCI, which has awarded WuXi AppTec an AA ESG rating for the past four years. Additionally, WuXi AppTec’s ESG performance has also been acknowledged by CDP and EcoVadis. In both 2023 and 2024, WuXi AppTec was listed in the S&P Global Sustainability Yearbook and in the FTSE4Good Index Series, and was named as an Industry and Regional “Top-Rated” company by Sustainalytics. In addition, WuXi AppTec drives sustainability by participating in ambitious global frameworks. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions, and in 2024 committed to the United Nations Global Compact (UNGC) in support of its ten sustainability principles. About WuXi AppTecAs a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
